Advanced search
1 file | 1.73 MB Add to list

Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis

Molood Shariati (UGent) , Wouter Willaert (UGent) , Wim Ceelen (UGent) , Stefaan De Smedt (UGent) and Katrien Remaut (UGent)
(2019) CANCERS. 11(7).
Author
Organization
Abstract
Recent advances in locoregional chemotherapy have opened the door to new approaches for the clinical management of peritoneal carcinomatosis (PC) by facilitating the delivery of anti-neoplastic agents directly to the tumor site, while mitigating adverse effects typically associated with systemic administration. In particular, an innovative intra-abdominal chemotherapeutic approach, known as Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC), was recently introduced to the intraperitoneal (IP) therapy regimens as a palliative therapeutic option in patients with PC, presumably providing a better drug distribution pattern together with deeper drug penetration into tumor nodules within the peritoneal space. Furthermore, the progress of nanotechnology in the past few decades has prompted the application of different nanomaterials in IP cancer therapy, offering new possibilities in this field ranging from an extended retention time to sustained drug release in the peritoneal cavity. This review highlights the progress, challenges, and opportunities in utilizing cancer nanotherapeutics for locoregional drug delivery, with a special emphasis on the aerosolization approach for intraperitoneal therapies.
Keywords
peritoneal carcinomatosis, PIPAC, nebulization, nanomedicine, localized chemotherapy, intraperitoneal administration, DRUG-DELIVERY SYSTEMS, PLATINUM-RESISTANT OVARIAN, INTRAPERITONEAL CHEMOTHERAPY, SUSTAINED-RELEASE, ELECTROSTATIC PRECIPITATION, INTRAABDOMINAL PRESSURE, TARGETED NANOPARTICLES, CANCER NANOTECHNOLOGY, TECHNICAL DESCRIPTION, DISTRIBUTION PATTERN

Downloads

  • 8621181.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.73 MB

Citation

Please use this url to cite or link to this publication:

MLA
Shariati, Molood, et al. “Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis.” CANCERS, vol. 11, no. 7, 2019, doi:10.3390/cancers11070906.
APA
Shariati, M., Willaert, W., Ceelen, W., De Smedt, S., & Remaut, K. (2019). Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis. CANCERS, 11(7). https://doi.org/10.3390/cancers11070906
Chicago author-date
Shariati, Molood, Wouter Willaert, Wim Ceelen, Stefaan De Smedt, and Katrien Remaut. 2019. “Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis.” CANCERS 11 (7). https://doi.org/10.3390/cancers11070906.
Chicago author-date (all authors)
Shariati, Molood, Wouter Willaert, Wim Ceelen, Stefaan De Smedt, and Katrien Remaut. 2019. “Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis.” CANCERS 11 (7). doi:10.3390/cancers11070906.
Vancouver
1.
Shariati M, Willaert W, Ceelen W, De Smedt S, Remaut K. Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis. CANCERS. 2019;11(7).
IEEE
[1]
M. Shariati, W. Willaert, W. Ceelen, S. De Smedt, and K. Remaut, “Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis,” CANCERS, vol. 11, no. 7, 2019.
@article{8622351,
  abstract     = {{Recent advances in locoregional chemotherapy have opened the door to new approaches for the clinical management of peritoneal carcinomatosis (PC) by facilitating the delivery of anti-neoplastic agents directly to the tumor site, while mitigating adverse effects typically associated with systemic administration. In particular, an innovative intra-abdominal chemotherapeutic approach, known as Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC), was recently introduced to the intraperitoneal (IP) therapy regimens as a palliative therapeutic option in patients with PC, presumably providing a better drug distribution pattern together with deeper drug penetration into tumor nodules within the peritoneal space. Furthermore, the progress of nanotechnology in the past few decades has prompted the application of different nanomaterials in IP cancer therapy, offering new possibilities in this field ranging from an extended retention time to sustained drug release in the peritoneal cavity. This review highlights the progress, challenges, and opportunities in utilizing cancer nanotherapeutics for locoregional drug delivery, with a special emphasis on the aerosolization approach for intraperitoneal therapies.}},
  articleno    = {{906}},
  author       = {{Shariati, Molood and Willaert, Wouter and Ceelen, Wim and De Smedt, Stefaan and Remaut, Katrien}},
  issn         = {{2072-6694}},
  journal      = {{CANCERS}},
  keywords     = {{peritoneal carcinomatosis,PIPAC,nebulization,nanomedicine,localized chemotherapy,intraperitoneal administration,DRUG-DELIVERY SYSTEMS,PLATINUM-RESISTANT OVARIAN,INTRAPERITONEAL CHEMOTHERAPY,SUSTAINED-RELEASE,ELECTROSTATIC PRECIPITATION,INTRAABDOMINAL PRESSURE,TARGETED NANOPARTICLES,CANCER NANOTECHNOLOGY,TECHNICAL DESCRIPTION,DISTRIBUTION PATTERN}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{20}},
  title        = {{Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis}},
  url          = {{http://doi.org/10.3390/cancers11070906}},
  volume       = {{11}},
  year         = {{2019}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: